“I was feeling really weak and shaky … I wasn’t eating enough to keep myself going.” That’s how one Australian mother, Emily, described her experience after starting a GLP-1 medication, as reported by smh.com.au. Her story highlights a growing concern: millions of people using GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro are at risk of malnutrition and muscle loss, but the full extent of these complications is not being systematically tracked, according to a new systematic review from the University of Newcastle.
The review, which assessed the diets of about 50,000 adults on GLP-1s, found a critical gap in the evidence focusing on the health hazards of rapid weight loss associated with these drugs. Extreme cases of malnutrition carry severe risks, including brain damage, heart problems, and death. While the powerful positive health effects of GLP-1s—such as significant weight loss and improved blood glucose control—are well-documented, researchers now stress an urgent need to address this hidden danger.
How Rapid Weight Loss Disrupts Nutrition at a Cellular Level
GLP-1 receptor agonists work by mimicking the glucagon-like peptide-1 hormone, which targets specific receptors in the brain to slow gastric emptying and increase feelings of satiety. This mechanism of action leads to a reduced appetite and a lower overall caloric intake. However, when people significantly cut down their food intake, they risk not getting enough protein to feed and protect their muscles.
You’re also not going to get enough of these vitamins and minerals that have specific roles in things like healing wounds, keeping your hair and nails growing, producing energy throughout your body or helping the neurons in your brain fire up,
Laureate Professor Clare Collins, a nutrition and dietetics expert from the University of Newcastle, explained. She noted that common side effects of the peptides—fatigue, nausea, diarrhoea, and constipation—overlap with symptoms of nutrient deficiencies, making them easy to miss or misattribute.
For instance, a thiamine deficiency can manifest as a loss of appetite, nausea, and tingling in the arms and legs. If left untreated, this can develop into Wernicke’s encephalopathy, a rare but severe neurological disorder that can lead to irreversible brain damage. Cases of this have been identified in people who have rapidly lost weight on GLP-1s. Similarly, a magnesium deficiency, which also presents with low appetite, nausea, and fatigue, can escalate to cardiac arrest in severe cases.
Drugs Risk Muscle Loss by Suppressing Appetite
- Appetite suppression can backfire: GLP-1 drugs reduce hunger, but this can lead to unintentionally consuming too few calories and not enough protein, risking muscle loss.
- Symptoms are deceiving: Feeling tired, nauseous, or shaky isn’t just a drug side effect; it could be a sign of a serious vitamin deficiency like B1 or magnesium.
- Muscle matters: Without enough protein, the body breaks down muscle tissue for energy, which weakens you and can lead to long-term health problems.
Evidence Gap Risks Monitoring for Nutritional Deficiency
The central issue, as identified by experts, is the lack of robust data. But are we not seeing it because people are still eating enough … [or] because we’re not testing for it?
asked Janet Franklin. This theoretical risk is becoming a reality for some, but its prevalence remains unknown due to insufficient monitoring.
Comparing Nutritional Risks Across GLP-1 Medications
| Medication | Primary Indication | Reported Malnutrition Risk | Key Nutritional Concern |
|---|---|---|---|
| Ozempic (semaglutide) | Type 2 Diabetes | Moderate | Protein & B1 Deficiency |
| Wegovy (semaglutide) | Weight Management | High | General Malnutrition & Muscle Loss |
| Mounjaro (tirzepatide) | Type 2 Diabetes | High | Protein & Magnesium Deficiency |
The Push for Proactive Patient Guidance and Commercial Adaptation
Clinicians are now recommending a multi-faceted approach: a diet rich in protein, the use of nutrient-dense meals, and increased intake of water, protein, fibre and micronutrients through smaller, more frequent meals. Hydration is also critical; drinking 1.5-2 litres of water daily is advised until urine is the colour of straw.
Prescribers are also being urged to take a more cautious approach. You’ve got to assess and monitor carefully … this is a really important opportunity for us not to cause harm.
said Dr Karen Spielman. She advocated for higher rebates for longer consultations to allow for thorough nutritional assessments and to screen for disordered eating, which has also been linked to GLP-1 use.
The industry is responding to the “Ozempic wave” with tailored products. notes that commercial food chains like Guzman y Gomez have expanded their mini-portion range, while meal kit service Marley Spoon’s “GLP-1 Support range”—featuring smaller, protein- and fibre-rich servings—has seen 110 per cent month-on-month growth since its launch.
Consult a Doctor for Severe Nutritional Symptoms
While GLP-1s can be life-changing for many, they are not suitable for everyone. Consult a healthcare provider immediately if you experience symptoms that suggest a severe nutritional deficiency or medical complication. These include:
- Severe, persistent weakness or dizziness
- Irregular heartbeat or palpitations
- Numbness or tingling in the hands and feet that does not subside
- Mental confusion, memory loss, or unusual eye movements
- Inability to eat or keep any food down for more than 24 hours
Experts agree that the clinical community must develop formal guidelines to manage these risks. As Dr. Spielman stated, developing clinical guidelines could increase awareness of disordered eating and nutrition risks, ensuring that the pursuit of metabolic health does not come at the cost of a patient’s overall well-being.
